Table 3.
Gut microbiome/metabolome in immunotherapy
| Gut microbiome/metabolome | Categories | Therapeutic outcome | Treatment | n | Study design | PMID |
|---|---|---|---|---|---|---|
| Actinomyces_sp_ICM47 | Bacterial species | Unfavorable | PD-1/PD-L1 inhibitors | 80 | Prospectively | PMID: 38844407 |
| Senegalimassilia_anaerobia | Bacterial species | Unfavorable | ||||
| galanthaminone | Metabolite | Favorable | ||||
| The diversity of bacteria and fungi | Favorable | |||||
| Bacteroides stercoris | Bacterial species | Favorable | Atezo + Bev | 37 | Retrospectively | PMID: 38730627 |
| Parabacteroides merdae | Bacterial species | Favorable | ||||
| Prevotella 9 | Bacterial species | Unfavorable | ICI (PD-(L)1 monotherapy: n = 24, combination with TKI: n = 17) | 41 | Prospectively | PMID: 35738801 |
| Lachnoclostridium | Bacterial species | Favorable | ||||
| Lachnospiraceae | Bacterial species | Favorable | ||||
| Veillonella | Bacterial species | Favorable |